Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 1,671 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 1,671 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $18.24, for a total value of $30,479.04. Following the completion of the transaction, the chief executive officer now owns 575,661 shares in the company, valued at approximately $10,500,056.64. This represents a 0.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Saurabh Saha also recently made the following trade(s):

• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total value of $350,839.00.
• On Friday, September 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.53, for a total value of $909,150.00.
• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.

Centessa Pharmaceuticals Trading Down 6.3 %

Shares of Centessa Pharmaceuticals stock opened at $17.04 on Friday. The business’s 50 day simple moving average is $16.09 and its 200 day simple moving average is $12.38. Centessa Pharmaceuticals plc has a 52-week low of $5.58 and a 52-week high of $18.74. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CNTA. Acadian Asset Management LLC acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $330,000. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $109,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock worth $33,427,000 after acquiring an additional 418,615 shares during the period. First Light Asset Management LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $33,923,000. Finally, Artal Group S.A. boosted its stake in shares of Centessa Pharmaceuticals by 39.5% during the 1st quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after acquiring an additional 400,000 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Guggenheim raised their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Finally, Jefferies Financial Group raised their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.